DOJ

Company

Last mentioned: Mar 13, 2026

Timeline

  1. Missouri Stay Request

    DOJ files request in Missouri court to pause litigation pending FDA review.

  2. DOJ Missouri Filing

    DOJ quietly asks the Missouri court to pause proceedings pending FDA review.

  3. Legislative Action

    Senator Josh Hawley introduces a Senate bill to outright ban the abortion pill.

  4. Legislative Action

    Sen. Josh Hawley introduces a Senate bill to outright ban the abortion pill.

  5. Louisiana Request

    DOJ asks Louisiana court to pause a similar lawsuit; request is largely ignored by the state.

  6. Louisiana Precedent

    DOJ unsuccessfully asks Louisiana to pause its separate anti-abortion lawsuit.

  7. Amended Complaint

    AG Catherine Hanaway files amended complaint targeting mail-order abortion drugs.

  8. Amended Complaint

    AG Catherine Hanaway adds claims that mail-order drugs are dangerous without in-person visits.

  9. Lawsuit Filed

    Missouri, Kansas, and Idaho file suit against the FDA over mifepristone approval.

  10. Lawsuit Filed

    Missouri, Kansas, and Idaho file suit against the FDA over mifepristone regulations.

Stories mentioning DOJ 2

regulation Bearish

DOJ Requests Pause in Missouri Mifepristone Lawsuit Citing Internal FDA Review

The U.S. Department of Justice has requested a federal court in Missouri to pause or dismiss a lawsuit targeting the FDA's approval of mifepristone, citing an ongoing internal agency review. This move reflects a strategic effort by the administration to manage high-stakes litigation over medication abortion and telehealth access ahead of the 2026 midterms.

2 sources
regulation Bearish

DOJ Seeks Strategic Pause in State-Led Mifepristone Litigation Amid FDA Review

The U.S. Department of Justice has requested federal courts in Missouri to pause litigation challenging the FDA's approval of mifepristone, citing an ongoing internal agency review. This tactical shift suggests a preference for administrative rulemaking over high-profile court battles as the administration navigates the legal complexities of reproductive health regulation.

2 sources